Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma

被引：17
|
作者：
Gautschi, Oliver [1 ]
Menon, Roopika [2 ]
Bertrand, Miriam [2 ]
Murer, Christian [1 ]
Diebold, Joachim [1 ]
机构：
[1] Cantonal Hosp Lucerne, Luzern, Switzerland
[2] NEO New Oncol GmbH, Cologne, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2019.07.027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E13 / E15
页数：4
相关论文
共 50 条
  • [21] Management of stage IA EGFR-mutant adenocarcinoma of the lung
    Pirker, Robert
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3260 - S3262
  • [22] Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy
    Elghawy, Omar
    Barsouk, Adam
    Reed-Guy, Lauren
    Stalker, Margaret
    Sussman, Jonathan
    Robinson, Kyle
    Kosteva, John
    Singh, Aditi
    Cohen, Roger B.
    Langer, Corey
    Ciunci, Christine
    D'Avella, Christopher
    Sun, Lova
    Marmarelis, Melina E.
    Aggarwal, Charu
    CLINICAL LUNG CANCER, 2025, 26 (02)
  • [23] Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
    Elkrief, Arielle
    Makhnin, Alex
    Moses, Khadeja A.
    Ahn, Linda S.
    Preeshagul, Isabel R.
    Iqbal, Afsheen N.
    Hayes, Sara A.
    Plodkowski, Andrew J.
    Paik, Paul K.
    Ladanyi, Marc
    Kris, Mark G.
    Riely, Gregory J.
    Michor, Franziska
    Yu, Helena A.
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1423 - 1428
  • [24] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers
    Qi, Chuang
    Cui, Huanxi
    Chen, Dongsheng
    JAMA ONCOLOGY, 2020, 6 (12)
  • [25] Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure
    Ding, H.
    Xu, T.
    Wang, X.
    Cheng, W.
    Fang, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S670 - S671
  • [26] Improving Therapy for EGFR-Mutant Lung Cancers
    Piotrowska, Zofia
    ONCOLOGIST, 2017, 22 : S4 - S4
  • [27] Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment
    Corassa, Marcelo
    Abreu, Rodrigo Fonseca
    Cordeiro de Lima, Vladmir Claudio
    Torrezan, Giovana Tardim
    Cavalher, Felicia Peterson
    Silva, Tullio Novaes
    de Oliveira, Thiago Bueno
    Freitas, Helano Carioca
    Carraro, Dirce Maria
    Costa, Felipe D'Almeida
    JCO PRECISION ONCOLOGY, 2022, 6
  • [28] Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib
    Wu, Jia-Jun
    Tseng, Jeng-Sen
    Zheng, Zhe-Rong
    Chu, Cheng-Hsiang
    Chen, Kun-Chieh
    Lin, Mong-Wei
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Yang, Tsung-Ying
    Yu, Sung-Liang
    Chen, Jin-Shing
    Ho, Chao-Chi
    Chang, Gee-Chen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [29] Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib
    Schmid, Sabine
    Stewart, Erin L.
    Martins-Filho, Sebastiao N.
    Cabanero, Michael
    Wang, Ao
    Bao, Hua
    Wu, Xue
    Patel, Deval
    Chen, Zhuo
    Law, Jennifer H.
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Leighl, Natasha
    Tsao, Ming-Sound
    Pugh, Trevor
    Bratman, Scott, V
    Sacher, Adrian
    Liu, Geoffrey
    CLINICAL LUNG CANCER, 2020, 21 (05) : E488 - E492
  • [30] Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response
    Kleczko, Emily K.
    Le, Anh T.
    Hinz, Trista K.
    Nguyen, Teresa T.
    Navarro, Andre
    Hu, Cheng-Jun
    Selman, Ana M.
    Clambey, Eric T.
    Merrick, Daniel T.
    Lu, Sizhao
    -Evans, Mary Weiser
    Nemenoff, Raphael A.
    Heasley, Lynn E.
    CANCER LETTERS, 2023, 556
12345